Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer https://t.co/oEHdFQC1VT
Caris’ AI-powered predictor MI FOLFOXai demonstrates 71% difference in overall survival for mCRC patients published in @CCR_AACR. https://t.co/1UCZ1W74Ur https://t.co/NREaLaD6eQ
El predictor impulsado por IA de Caris ayuda a medir qué pacientes con cáncer colorrectal metastásico se beneficiarán del tratamiento con el régimen de atención estándar actual. (Publicado a través de American Association for Cancer Research ) https://t.co
RT @carisls: Caris' AI-powered predictor helps gauge which metastatic colorectal cancer patients will benefit from treatment with current s…
Caris' AI-powered predictor helps gauge which metastatic colorectal cancer patients will benefit from treatment with current standard of care regimen. (Published via @CCR_AACR) https://t.co/iUtAxs74mo https://t.co/SozYpvJOlo
Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer https://t.co/2wR0Dc1kTn
Validation studies published in @CCR_AACR illustrate a 71% difference in overall survival for mCRC patients using Caris' AI-powered predictor MI FOLFOXai. https://t.co/iUtAxs74mo https://t.co/DNO02CpYe8
Validated across two independent studies in @CCR_AACR, MI FOLFOXai helps physicians better determine the relative benefit colorectal cancer patients will receive from current standard of care regimen. https://t.co/iUtAxs74mo https://t.co/GkO9TLx99g
RT @carisls: Caris’ AI-powered predictor helps gauge which metastatic colorectal cancer patients will benefit from treatment with current s…
RT @carisls: Caris’ AI-powered predictor helps gauge which metastatic colorectal cancer patients will benefit from treatment with current s…
RT @carisls: Caris’ AI-powered predictor helps gauge which metastatic colorectal cancer patients will benefit from treatment with current s…
RT @carisls: Caris’ AI-powered predictor helps gauge which metastatic colorectal cancer patients will benefit from treatment with current s…
Caris’ AI-powered predictor helps gauge which metastatic colorectal cancer patients will benefit from treatment with current standard of care regimen validated across two independent studies in @CCR_AACR. https://t.co/iUtAxs74mo https://t.co/Gn0xJ57aAq
Clinical validation of a machine-learning derived signature predictive of outcomes from first-line oxaliplatin-based #chemotherapy in advanced #colorectalcancer. #CRC https://t.co/Dm1ebvWFLO
RT @Marindoc: Excited to report publication of FOLFOXai, the first AI-powered and validated predictor of chemotherapy efficacy in advanced…
RT @Marindoc: Excited to report publication of FOLFOXai, the first AI-powered and validated predictor of chemotherapy efficacy in advanced…
Clinical validation of a machine-learning derived signature predictive of outcomes from first-line oxaliplatin-based chemotherapy in advanced colorectal cancer https://t.co/KxAQpoU3O7
RT @jamienholloway: Using artificial intelligence and next gen sequencing to improve outcomes in metastatic colorectal cancer patients from…
RT @CancerCureNow: Clinical validation of a machine-learning derived signature predictive of outcomes from first-line oxaliplatin-based che…
Clinical validation of a machine-learning derived signature predictive of outcomes from first-line oxaliplatin-based chemotherapy in advanced colorectal cancer https://t.co/vfqTa8xpjc
Read the article here: https://t.co/ZzVEFkSS2l
Question: Can one identify a genomic signature that predicts patient survival after treatment with FOLFOX? Answer: Yes. Clinical validation of a machine-learning derived signature predictive of outcomes ... in advanced colorectal cancer https://t.co/h5fZ
Using artificial intelligence and next gen sequencing to improve outcomes in metastatic colorectal cancer patients from @carisls: https://t.co/NO67rogsQJ